title: Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
abstract: The discovery of thrombolytic agents goes back to the 1930s, when it was shown that substances derived from bacteria (streptokinase, staphylokinase), tissue (fibrinokinase), urine (urokinase) or bat saliva could activate the fibrinolytic system. The potential to treat arterial thrombosis with plasmin was recognized, but it was not until 1958 that its first use in acute ischaemic stroke (AIS) was described. However, since computer tomography (CT) was not available until the mid 1970s, optimal selection of patients was not possible. Early studies with streptokinase in AIS showed an increased risk of intracranial haemorrhage and lack of efficacy, which was associated with low fibrin specificity. The search for new agents with a better risk-benefit profile continued until 1979 when tissue plasminogen activator (t-PA) was discovered. In 1983 it became possible to produce recombinant t-PA (rt-PA) by expression of a cloned gene which enabled clinical trials to be started, mainly for coronary thrombolysis. In 1995, the National Institute of Neurological Disorders and Stroke study showed that rt-PA was an effective treatment for AIS, nowadays for use up to 4.5 h after onset. However, rt-PA still often fails in achieving rapid reperfusion, has relatively low recanalization rates and is associated with an increased bleeding risk. Several attempts have been made to develop thrombolytics with a better risk-benefit profile than rt-PA, but no real impact on clinical practice was observed. In 1994, it was shown that tenecteplase (rt-PA-TNK) had a higher fibrin specificity than rt-PA, but its clinical use in AIS was described only in 2005. The recently reported results of a small phase 2B trial showed significantly better reperfusion and clinical outcome with rt-PA-TNK compared to rt-PA; patients were selected by CT perfusion and angiography, and treated within 6 h after stroke onset. Currently, a phase 3 trial of rt-PA-TNK versus rt-PA is being planned in patients at an onset up to 4.5 h. The most fibrin-specific recombinant plasminogen activator desmoteplase originates from 1991, and its clinical development in AIS started in 2005. Desmoteplase is in phase 3 development for the treatment of AIS between 3 and 9 h after onset in AIS patients presenting with occlusion or high-grade stenosis.
authors.affiliation: Department of Neurology, Asklepios Klinik Altona, Hamburg, Germany. j.roether@asklepios.com
authors.forename: Joachim
authors.initials: J
authors.lastname: Röther
authors.forename: Gary A
authors.initials: GA
authors.lastname: Ford
authors.forename: Vincent N S
authors.initials: VN
authors.lastname: Thijs
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000266:history; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000266:history; D005544:Forecasting; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D020521:Stroke / Q000175:diagnosis / Q000188:drug therapy* / Q000266:history; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000266:history / Q000639:trends; D061665:Time-to-Treatment; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator